Clinical Trial Update: Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male [Phase 1]

View source ↗

Summary

Phase 1 trial comparing IBI305 and bevacizumab in healthy male subjects assessing pharmacokinetics, safety, and immunogenicity with completed status and posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• IBI305 (bevacizumab biosimilar)
• bevazizumab (bevacizumab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Healthy | Phase 1 | Status: COMPLETED | Results posted: 2020-11-04